Asset Details

MbrlCatalogueTitleDetail

Do you wish to reserve the book?

Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer

by van der Heijden, Michiel S. , Yu, Xuesong , Valderrama, Begoña P. , Mar, Nataliya , Castellano, Daniel , Drakaki, Alexandra , Narayanan, Sujata , Fornarini, Giuseppe , Iyer, Gopa , Shin, Sang Joon , Kikuchi, Eiji , Vulsteke, Christof , Park, Se Hoon , Loriot, Yohann , Hoffman-Censits, Jean , Gorla, Seema , Bedke, Jens , Li, Jian-Ri , Fléchon, Aude , Homet Moreno, Blanca , Gümüş, Mahmut , Duran, Ignacio , Powles, Thomas , Gupta, Shilpa

in Antibodies, Monoclonal - administration & dosage / Antibodies, Monoclonal - adverse effects / Antibodies, Monoclonal - therapeutic use / Antibodies, Monoclonal, Humanized - administration & dosage / Antibodies, Monoclonal, Humanized - adverse effects / Antibodies, Monoclonal, Humanized - therapeutic use / Antineoplastic Agents - administration & dosage / Antineoplastic Agents - adverse effects / Antineoplastic Agents - therapeutic use / Bladder cancer / Body weight / Cancer / Carboplatin / Carboplatin - administration & dosage / Carboplatin - adverse effects / Carboplatin - therapeutic use / Carcinoma, Transitional Cell - drug therapy / Carcinoma, Transitional Cell - pathology / Carcinoma, Transitional Cell - secondary / Chemotherapy / Cisplatin / Cisplatin - administration & dosage / Cisplatin - adverse effects / Cisplatin - therapeutic use / Clinical outcomes / Drug dosages / Gemcitabine / Gemcitabine - administration & dosage / Gemcitabine - adverse effects / Gemcitabine - therapeutic use / Genitourinary Cancer / Hematology / Humans / Immunotherapy / Metastases / Metastasis / Monoclonal antibodies / Oncology / Patients / Pembrolizumab / Platinum / Prostate Disease / Prostate Disease General / Safety / Survival / Survival Analysis / Targeted cancer therapy / Treatments in Oncology / Urinary Bladder Neoplasms / Urologic Neoplasms - drug therapy / Urologic Neoplasms - pathology / Urologic Neoplasms - secondary / Urology / Urothelial cancer / Urothelial carcinoma

2024

Yes Please

Hey, we have placed the reservation for you!

By the way, why not check out events that you can attend while you pick your title.

Oops! Something went wrong.

Looks like we were not able to place the reservation. Kindly try again later.

Are you sure you want to remove the book from the shelf?

Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer

2024

Confirm

Do you wish to request the book?

Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer

2024

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy

How would you like to get it?

Submit

We have requested the book for you!

Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.

Oops! Something went wrong.

Looks like we were not able to place your request. Kindly try again later.

Journal Article

Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer

van der Heijden, Michiel S.,

Yu, Xuesong,

Valderrama, Begoña P.,

Mar, Nataliya,

Castellano, Daniel,

Drakaki, Alexandra,

Narayanan, Sujata,

Fornarini, Giuseppe,

Iyer, Gopa,

Shin, Sang Joon,

Kikuchi, Eiji,

Vulsteke, Christof,

Park, Se Hoon,

Loriot, Yohann,

Hoffman-Censits, Jean,

Gorla, Seema,

Bedke, Jens,

Li, Jian-Ri,

Fléchon, Aude,

Homet Moreno, Blanca,

Gümüş, Mahmut,

Duran, Ignacio,

Powles, Thomas,

Gupta, Shilpa

2024

Overview

In a trial comparing enfortumab vedotin and a PD-1 inhibitor with chemotherapy in patients with untreated advanced or metastatic urothelial cancer, progression-free and overall survival nearly doubled with the experimental treatment.

Share this book

Add to My Shelf

Publisher

Massachusetts Medical Society

Subject

Antibodies, Monoclonal - administration & dosage

/ Antibodies, Monoclonal - adverse effects

/ Antibodies, Monoclonal - therapeutic use

/ Antibodies, Monoclonal, Humanized - administration & dosage

/ Antibodies, Monoclonal, Humanized - adverse effects

/ Antibodies, Monoclonal, Humanized - therapeutic use

/ Antineoplastic Agents - administration & dosage